Neil Poulter FMedSci
Professor of Preventive Cardiovascular Medicine
Imperial College London
London, United Kingdom
Professor Neil Poulter qualified at St Mary’s Hospital, London, in 1974, following which he trained in General Medicine. He then spent 5 years in Kenya co-ordinating a collaborative hypertension research programme at the Wellcome Trust Research Laboratories in Nairobi.
On his return to the UK in 1985 he gained an MSc in Epidemiology with distinction at the London School of Hygiene and Tropical Medicine. Following this he was Co-PI of the WHO Oral Contraceptive case-control Study at University College London Medical School.
In 1997 he was appointed Professor of Preventive Cardiovascular Medicine at Imperial College London, where he is currently co-Director of the International Centre for Circulatory Health and Director of the Imperial Clinical Trials Unit. He is an Honorary Consultant Physician and Epidemiologist at the Peart-Rose (CVD Prevention) Clinic based at Hammersmith Hospital, London, where he is actively involved in the treatment of patients with hypertension and related problems.
He was President of the British Hypertension Society from 2003-2005 and is currently President of the International Society of Hypertension. In 2008, he was elected as one of the Inaugural Senior Investigators of the NIHR and also elected as a fellow of the Academy of Medical Sciences in 2009.
He has contributed chapters to several major textbooks and published over 430 papers in peer-reviewed medical journals, including co-authoring several sets of national and international guidelines. Professor Poulter is among the top 1% most cited academics in clinical medicine as reported in the Thomson Reuters Highly Cited Researcher 2014 report.
He has played a senior management role in several international trials including the ASCOT, ADVANCE, EXSCEL, DEVOTE and LEADER trials; other research activities include the optimal investigation and management of essential hypertension and dyslipidaemia; the association between birth weight and various cardiovascular risk factors; the cardiovascular effects of exogenous oestrogen and progesterone; the prevention and aetiology of type 2 diabetes and abdominal aortic aneurism; and ethnic differences in cardiovascular disease.
Professor Kausik Ray
Kausik Kumar Ray is currently Professor of Public Heath, Department of Public Health and Primary Care, School of Public Health, Imperial College London. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and European Atherosclerosis Society also serving on the EAS Consensus panel. Professor Ray has been the national lead investigator (SC or EC member) for several major medical trials, and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS.
Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 40 and i10 of 69 and more than 23,000 citations overall, including over 170 publications in journals including NEJM, Lancet, JAMA, Archives of Internal Medicine, Circulation, the Journal of the American College of Cardiology, and the European Heart Journal. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH and includes 55 countries, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250 000 people in London.
Professor David Wood
Clinical Professor of Cardiovascular Medicine and Honorary Consultant Cardiologist National Heart and Lung Institute, Imperial College London
MB ChB, MSc, FRCP, FRCPE, FFPHM, FESC, FACC, FAHA
Professor Wood is a cardiologist committed to prevention of cardiovascular disease and holds joint academic appointments at Imperial College and the National University of Ireland-Galway. He has contributed to international policy and guidelines on cardiovascular disease (CVD) prevention through the World Health Organisation, World Heart Federation and the European Society of Cardiology. He was a founder and President of the European Association for Cardiovascular Prevention and Rehabilitation, a Board member of the European Society of Cardiology, where he served as Secretary/Treasurer, and in 2014 he was elected as President-Elect of the World Heart Federation and is currently serving his term as President 2017-2018.
He is the principal investigator for the ASPIRE and EUROASPIRE studies across 27 European countries, evaluating standards of preventive cardiology practice in hospital and primary care. He led the EUROACTION and EUROACTION+ trials in preventive cardiology evaluating nurse- led models of preventive care in hospital and general practice across 8 European countries, and the principals of EUROACTION are now incorporated in the Imperial College NHS Cardiovascular Health programme for the NHS.
He is Course Director for the Imperial College Masters degree programme in Preventive Cardiology providing education and training for doctors, nurses and allied health professionals. He is Senior Editor of the European Society of Cardiology Textbook of Preventive Cardiology and also founded the European Journal of Cardiovascular Prevention and Rehabilitation (now European Journal of Preventive Cardiology) and served as the first Joint Editor in Chief.
He is married to Dr Catriona Jennings, a cardiovascular specialist nurse, and they have four adult children. He enjoys cooking for family and friends and also sailing, presently circumnavigating the UK in a Frances 26 sailing boat.
Professor Theresa A McDonagh
MD, FRCP, FESC
Consultant Cardiologist, and Clinical Lead for Cardiology and Heart Failure
King’s College Hospital, Denmark Hill, London,
Professor McDonagh qualified from the University of Edinburgh and completed her internal medicine training there. She trained in Cardiology at the Western Infirmary in Glasgow. Her main research was on the epidemiology of Left Ventricular Dysfunction and Natriuretic Peptides hormones.
Subsequently she was appointed as a Senior Lecturer at the University of Glasgow and Glasgow Royal Infirmary where she ran the Heart Failure Service and was the Cardiologist involved in the Heart Transplant Programme (1999-2004). Following this she was a Consultant Cardiologist at the Royal Brompton Hospital, London (2004-2011) where led the Heart Failure Service, before moving to King’s College Hospital to head up the Heart Failure Programme.
Her main research interests are in novel biomarkers for heart failure and the delivery of heart failure services.
She is a past Chair of the British Society for Heart Failure a Past Chair of the Clinical Section of the Heart Failure Association of the European Society of Cardiology. She is the Clinical Lead for the National Heart Failure Audit.
Professor Miles Fisher
Consultant Physician, Royal Infirmary, Glasgow, Scotland
Miles Fisher graduated from the University of Glasgow in 1979. He received his MD in 1988 for his thesis on ‘Evidence for a diabetic cardiopathy.’ He has been a consultant physician at Glasgow Royal Infirmary since 2001. In 2010 he was made an Honorary Professor at the University of Glasgow. He was a Vice-President (Medical) of the Royal College of Physicians and Surgeons of Glasgow from 2011-14, was the President of the Scottish Society of Physicians for 2015-16, and Co-chair of Scottish Heart & Arterial disease Risk Prevention (SHARP) in 2017.
He was on the steering committee of the DIGAMI 2 study and was the Scottish co-ordinator. He was an events adjudicator for the HOPE, HOPE-TOO, and ACE studies, and for the albiglutide Harmony phase 3 programme.
He has interests in diabetes and the heart, hypoglycaemia, and new treatments for diabetes. He is the editor or co-editor of four books on heart disease in diabetes, three books on hypoglycaemia, and a book on SGLT2 inhibitors. He is the author or co-author of 49 book chapters, 80 original papers, 70 review articles, 33 leaders and editorials, 52 drug notes for Practical Diabetes and 15 drug notes for the British Journal of Cardiology. He was the co-author of the diabetes chapter in the 19th, 20th and 21st Editions of Davidson’s Principles and Practice of Medicine.
Professor David Wheeler
Kidney Medicine at University College London, UK
David is Professor of Kidney Medicine at University College London, UK and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinician scientist interested in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid lowering regimens, calcimimetics and sodium glucose cotransporter 2 inhibitors in patients chronic kidney disease. He has developed clinical practice guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO), of which he is currently Co-Chair. He is Past President of the UK Renal Association, past chair of the UK Renal Registry and currently National Institute for Health Research (NIHR) National Specialty Lead for Nephrology.
Dr Mark Evans
Mark Evans qualified from St Bartholomews Hospital and completed clinical training in London, including time in clinical research at Kings (MD with Stephanie Amiel) followed by 3 years in pre-clinical research at Yale in Robert Sherwin’s laboratory. Since 2002, he has been a Consultant in diabetes and Internal Medicine at the Addenbrooke’s Teaching Hospital in Cambridge, and a University of Cambridge Lecturer in the Institute of Metabolic Science (www.ims.cam.ac.uk) and Department of Medicine.
His clinical and academic interests are in hypoglycaemia, type 1 diabetes, medical technology and structured education in diabetes. He is a member of the UK National DAFNE executive, the Department of Transport Honorary medical panel on driving and diabetes and the Diabetes Technology Network (DTN-UK).
Clifford J. Bailey, PhD, FRCP(Edin), FRCPath
Life and Health Sciences, Aston University, Birmingham, UK
Cliff Bailey is Professor of Clinical Science at Aston University in Birmingham, England. He is a Fellow of the Royal College of Physicians of Edinburgh and a Fellow of the Royal College of Pathologists. He has been a Royal Society visiting scientist at the University of Southern California, Los Angeles, and a visiting scientist at Hanover Medical School in Germany. He has served on medical and scientific committees of Diabetes UK (formerly the British Diabetic Association), Society for Endocrinology, and European Association for the Study of Diabetes.
Professor Bailey has held various editorial positions, including endocrine section editor of British Journal of Pharmacology and editorial board member of Diabetes, Obesity and Metabolism, LancetDE and Primary Care Diabetes. He is presently senior editor of Diabetes and Vascular Disease Research. He has been an expert witness for drug licensing authorities, regulatory agencies and other national and international review bodies. He received the 2013 Lunar Society medal and the 2015 Banting Lecture award. His research is mainly directed towards the pathogenesis and treatment of diabetes, especially the development of new agents to improve insulin action and reduce obesity, and the therapeutic application of surrogate beta-cells. He has published extensively with over 400 research papers and reviews, and four books.
Find out more
About the Meeting
We explored the latest techniques and developments in cardio-metabolic science.
The invited faculty delivered an innovative, comprehensive and educational programme.
The Meeting took place at Imperial College's Translation and Innovation Hub.